Ondansetron for the Treatment of Methamphetamine Dependence - 1

Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00040053

Enrollment

154

Registered

2002-06-18

Start date

2002-06-30

Completion date

2004-02-29

Last updated

2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amphetamine-Related Disorders

Keywords

amphetamine dependence

Brief summary

The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.

Detailed description

This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.

Interventions

DRUGOndansetron

Study design

Allocation

RANDOMIZED

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

18 years of age. Treatment seeking for meth dependence.

Exclusion criteria

Please contact site director for more details.

Design outcomes

Primary

Measure	Time frame
Clinicial improvement	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026